The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 38.22%.However, over the last six months, we can see a weaker performance of 159.17%. Over the last 30 days, the price of VRAX has fallen by 78.74%. And in the last five days, it has surged by 48.10%.
The stock market performance of Virax Biolabs Group Ltd has been very steady. Over the last year, the company’s stock hit its highest at $9.00 on 08/19/24, while the lowest price during the same time frame was $0.60, recorded on 05/03/24.
52-week price history of VRAX Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Virax Biolabs Group Ltd’s current trading price is -65.44% away from its 52-week high, while its distance from the 52-week low is 418.33%. The stock’s price range for this period has been between $0.60 and $9.00. The Healthcare sector company’s shares saw a trading volume of about 2.01 million for the day, which was higher than the average daily volume of 1.8 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Virax Biolabs Group Ltd (VRAX) has experienced a quarterly rise of 60.31% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 13.50M and boasts a workforce of 17 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.41, with a change in price of +1.81. Similarly, Virax Biolabs Group Ltd recorded 4,074,760 in trading volume during the last 100 days, posting a change of +139.23%.
VRAX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for VRAX stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.04.
VRAX Stock Stochastic Average
As of today, the raw stochastic average of Virax Biolabs Group Ltd over the past 50 days is 94.66%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 94.66%. Additionally, the Stochastic %K and %D values for the company were 82.28% and 79.95%, respectively, over the past 20 days.
